recognizing revenue as these treatment courses are delivered, there is no cash consideration for these treatment courses.
(a)
The decrease in revenues from the U.S. government as a percentage of
Total revenues
for 2024 and 2023 compared to 2022 was primarily due to the transition of Comirnaty and Paxlovid to commercial market sales in the second half of 2023 as well as the revenue reversal for Paxlovid in the fourth quarter of 2023.
Collectively, our three largest U.S. wholesaler customers represented
34
% and
42
% of total trade accounts receivable as of December 31, 2024 and December 31, 2023, respectively. Accounts receivable from the U.S. government as of December 31, 2024 and December 31, 2023 were not material to our consolidated financial statements.
Significant Revenues by Product
The following provides detailed revenue information for several of our major products:
Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
(a)
Reflects Alliance revenues and product revenues.
(b)
2024 includes (i) a $
771
million favorable final adjustment recorded in the first quarter to the estimated non-cash revenue reversal of $
3.5
billion recorded in the fourth quarter of 2023, reflecting
5.1
million EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated
6.5
million treatment courses that were expected to be returned as of December 31, 2023, and (ii) $
442
million of revenue recorded in the third quarter in connection with the creation of the U.S. SNS. 2023 includes a non-cash revenue reversal of $
3.5
billion recorded in the fourth quarter, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated
6.5
million treatment courses of EUA-labeled U.S. government inventory.
(c)
2024 includes $
129
million related to a one-time sales true-up settlement agreement with our commercialization partner.
(d)
In September 2024, we announced our voluntary withdrawal of all lots of Oxbryta for the treatment of sickle cell disease in all markets where it is approved, as well as the discontinuation of expanded access programs worldwide, based on the totality of clinical data that indicated at that time the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events, which requires further assessment that remains ongoing.
(e)
Includes, among other Hospital products, amounts previously presented as All other Anti-infectives and Ig Portfolio.
(f)
Primarily reflects Alliance revenues and royalty revenues.
(g)
Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Retacrit, Ruxience, Zirabev, Trazimera and Nivestym.
(h)
Erbitux is a registered trademark of ImClone LLC.
(i)
PC1 includes revenues from our contract manufacturing and our active pharmaceutical